FDA Regulation of Cosmetic Products
Cosmetics are a part of daily life for millions of people—but what many consumers and businesses don’t realize is that cosmetic products are regulated by the U.S. Food and Drug Administration (FDA). While cosmetics do not require FDA approval before going to market, they must be safe for use, properly labeled, and free from misleading claims.
This page provides a clear overview of how the FDA regulates cosmetics under the Federal Food, Drug, and Cosmetic Act (FD&C Act), the distinctions between cosmetics and drugs, and the responsibilities of manufacturers and distributors. Whether you’re a consumer, formulator, or importer, understanding these regulatory requirements is essential to ensure compliance and protect public health.
Definition of a Cosmetic (Per FD&C Act, Sec. 201(i))
The FDA defines a cosmetic as:
“Articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body… for cleansing, beautifying, promoting attractiveness, or altering the appearance.”
This includes:
- Skin moisturizers
- Perfumes and colognes
- Lipsticks and nail polishes
- Makeup (foundation, eyeshadow, etc.)
- Shampoos, conditioners
- Deodorants (but not antiperspirants—those are drugs)
NOT included: Products that are intended to treat or prevent disease or affect the structure/function of the body – these are drugs, even if they are applied topically.
Key Regulatory Features
- Pre-market Approval
- No FDA premarket approval is required for most cosmetics.
- Exception: Color additives (e.g., dyes used in eye makeup) must be FDA-approved for their specific use.
- Labeling
- Must comply with 21 CFR Part 701 (labeling) and 740 (warning statements).
- Requires:
- Identity of the product
- Net contents
- Ingredient declaration (descending order)
- Manufacturer/distributor info
- Any necessary warnings
- Good Manufacturing Practice (GMP)
- Unlike drugs, there are no mandatory GMP regulations for cosmetics—but the FDA recommends following voluntary GMP guidelines to ensure safety and quality.
- Adverse Event Reporting (MoCRA Update, 2022)
The Modernization of Cosmetics Regulation Act (MoCRA) now requires:
- Serious adverse event reporting (as of December 2023)
- Facility registration and product listing (with FDA, beginning July 2024)
- Safety substantiation: Companies must maintain documentation that products are safe under labeled conditions of use
- Identification and Listing
- Product listing and facility registration are voluntary (historically) but become mandatory under MoCRA.
- No National Drug Code (NDC) or formal registration number is required (unlike drugs).
Key Distinctions:
|
Feature |
OTC Drug |
Cosmetic |
|
Primary Purpose |
Treat or prevent disease, or affect body function |
Cleanse, beautify, or alter appearance |
|
FDA Premarket Approval |
Required (for NDA); not for monographs |
Not required (except color additives) |
|
GMP |
Mandatory (21 CFR 210/211) |
Voluntary (but encouraged) |
|
Labeling Requirements |
Strict (Drug Facts panel) |
Identity, contents, warnings |
|
Adverse Event Reporting |
Required |
Required under MoCRA |
International Notes
- EU: Cosmetics are highly regulated under Regulation (EC) No. 1223/2009. Products must have a Responsible Person, undergo a safety assessment, and be registered in the CPNP database.
- Canada: Regulated by Health Canada; require Cosmetic Notification Form, proper labeling, and safety substantiation.
- Japan and ASEAN countries have similar frameworks with strict labeling and ingredient restrictions.
Fresenius Kabi Recalls Ivenix Infusion Pump Software
Urgent Class I Recall Notice A crucial recall notice has been issued by Fresenius Kabi USA, LLC for the LVP Software of the Ivenix Infusion System (IIS), Version 5.8.0, distributed between March 6, 2023, and March 20, 2024. The recall, initiated on March 7, 2024, is...
Urgent Recall for Boston Scientific Obsidio Conformable Embolic
Urgent Class I Recall Notice Boston Scientific Corporation issued a critical recall notice on February 20, 2024, for its Obsidio Conformable Embolic products. The recall affects products distributed between May 8, 2023, and February 8, 2024. Product Details ...
FDA – Do Not Use Non-piercing Devices to Measure Blood Glucose
FDA Safety Communication On February 21, 2024 the U.S. Food and Drug Administration (FDA) issued a safety communication regarding the use of smartwatches or smart rings that claim to measure blood glucose levels without the need for skin piercing. Its cautionary...